Business Context and Reporting Period
Company: Impact BioMedical, Inc. (NYSE American: IBO)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: The Company discovers and patents technologies for human healthcare and wellness, focusing on biopharmaceuticals, wellness offerings, and drug discovery. Key proprietary technologies include Linebacker (oncology/inflammation), Laetose (metabolic health), 3F (functional fragrances), and Equivir (antiviral). The Company operates through several subsidiaries and relies on licensing and strategic partnerships for commercialization.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Total Revenue | $7,000 | $0 |
| Operating Loss | $(2,165,000) | $(1,396,000) |
| Net Loss | $(15,631,000) | $(1,880,000) |
| Net Loss Attributable to Common Stockholders | $(15,614,000) | $(1,849,000) |
| Cash and Cash Equivalents (End of Period) | $624,000 | $2,000 |
| Net Cash Used in Operating Activities | $(1,376,000) | $(867,000) |
| Total Assets | $19,060,000 | $20,290,000 |
| Total Liabilities | $26,440,000 | $13,053,000 |
| Stockholders' Deficit | $(7,380,000) | $7,237,000 |
Debt and Liquidity: As of June 30, 2025, the Company held a related-party note payable of $22,352,000. This balance includes a significant fair value adjustment. Cash on hand decreased from $1,999,000 at year-end 2024 to $624,000.
Material Changes vs. Prior Period
- Net Loss Expansion: Net loss increased by approximately 731% year-over-year for the six-month period, rising from $(1.88) million to $(15.63) million.
- Non-Cash Fair Value Adjustment: The primary driver of the increased loss was a non-cash charge of $12,942,000 recorded as a "Change in fair value of note payable, related party." This resulted from the remeasurement of a related-party debt instrument amended in September 2024 to allow settlement in equity.
- Expense Increases:
- Professional Fees: Increased 232% to $634,000, driven by legal and consulting services for business plan execution and M&A due diligence.
- Other Operating Expenses: Increased 1,380% to $226,000, primarily due to directors and officers insurance costs post-IPO.
- Compensation: Sales, general, and administrative compensation rose 68% to $495,000 due to increased headcount and bonus accruals.
- Revenue Recognition: The Company recorded $7,000 in revenue from biotech retail sales (Celios air purification), compared to zero in the prior year.
- Balance Sheet Deterioration: Total liabilities more than doubled to $26.44 million, while stockholders' equity shifted from a positive $7.24 million to a deficit of $(7.38) million.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The filing explicitly states that the Company's operating losses and negative cash flows raise substantial doubt about its ability to continue as a going concern within one year of the report date. Management plans to monetize intellectual property and control costs to address this.
- Unusual Items: The $12.9 million fair value adjustment on the related-party note is a significant non-cash item distorting the net loss. Additionally, the Company acquired assets from DSS PureAir, Inc. (a related party) for $1.15 million, paid via stock issuance.
- Subsequent Events: The Company entered into a Merger and Share Exchange Agreement with Dr. Ashleys Limited, anticipated to close in the fourth quarter of 2025.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2025, citing material weaknesses identified in the prior year's 10-K that remained unremediated.
- Risks: The Company has not generated significant revenues historically. Future success depends on licensing deals, milestone payments, and the commercialization of technologies which are still in development.
Investor Verification Checklist
- Debt Settlement Terms: Verify the specific terms of the related-party note payable ($22.35M) and the likelihood of settlement in cash versus equity, given the fair value accounting treatment.
- Liquidity Runway: Assess the sufficiency of the $624,000 cash balance against the $1.38M operating cash burn rate for the six-month period.
- Merger Status: Confirm the progress and regulatory status of the proposed merger with Dr. Ashleys Limited.
- Revenue Sustainability: Evaluate the scalability of the $7,000 revenue stream from Celios air purification sales.
- Internal Controls: Review the remediation plan for the material weaknesses in internal controls over financial reporting.